{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:09:56Z","timestamp":1790500196639,"version":"4.1.0"},"reference-count":50,"publisher":"National Academy of Sciences","issue":"38","license":[{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"vor","delay-in-days":181,"URL":"http:\/\/www.pnas.org\/site\/aboutpnas\/licenses.xhtml"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["100320\/Z\/12\/Z"],"award-info":[{"award-number":["100320\/Z\/12\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["105021\/Z\/14\/Z"],"award-info":[{"award-number":["105021\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["203134\/Z\/16\/Z"],"award-info":[{"award-number":["203134\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"uk medical research council","doi-asserted-by":"crossref","award":["MR\/K008749\/1"],"award-info":[{"award-number":["MR\/K008749\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2018,9,18]]},"abstract":"<jats:p>\n                    African trypanosomes cause lethal and neglected tropical diseases, known as sleeping sickness in humans and nagana in animals. Current therapies are limited, but fortunately, promising therapies are in advanced clinical and veterinary development, including acoziborole (AN5568 or SCYX-7158) and AN11736, respectively. These benzoxaboroles will likely be key to the World Health Organization\u2019s target of disease control by 2030. Their mode of action was previously unknown. We have developed a high-coverage overexpression library and use it here to explore drug mode of action in\n                    <jats:italic>Trypanosoma brucei<\/jats:italic>\n                    . Initially, an inhibitor with a known target was used to select for drug resistance and to test massive parallel library screening and genome-wide mapping; this effectively identified the known target and validated the approach. Subsequently, the overexpression screening approach was used to identify the target of the benzoxaboroles, Cleavage and Polyadenylation Specificity Factor 3 (CPSF3, Tb927.4.1340). We validated the CPSF3 endonuclease as the target, using independent overexpression strains. Knockdown provided genetic validation of CPSF3 as essential, and GFP tagging confirmed the expected nuclear localization. Molecular docking and CRISPR-Cas9-based editing demonstrated how acoziborole can specifically block the active site and mRNA processing by parasite, but not host CPSF3. Thus, our findings provide both genetic and chemical validation for CPSF3 as an important drug target in trypanosomes and reveal inhibition of mRNA maturation as the mode of action of the trypanocidal benzoxaboroles. Understanding the mechanism of action of benzoxaborole-based therapies can assist development of improved therapies, as well as the prediction and monitoring of resistance, if or when it arises.\n                  <\/jats:p>","DOI":"10.1073\/pnas.1807915115","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T15:30:30Z","timestamp":1536161430000},"page":"9616-9621","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":129,"title":["Clinical and veterinary trypanocidal benzoxaboroles target CPSF3"],"prefix":"10.1073","volume":"115","author":[{"given":"Richard J.","family":"Wall","sequence":"first","affiliation":[{"name":"The Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, DD1 5EH Dundee, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rico","sequence":"additional","affiliation":[{"name":"The Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, DD1 5EH Dundee, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Lukac","sequence":"additional","affiliation":[{"name":"The Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, DD1 5EH Dundee, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Zuccotto","sequence":"additional","affiliation":[{"name":"The Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, DD1 5EH Dundee, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Elg","sequence":"additional","affiliation":[{"name":"The Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, DD1 5EH Dundee, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"The Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, DD1 5EH Dundee, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Freund","sequence":"additional","affiliation":[{"name":"Anacor Pharmaceuticals, Inc., Palo Alto, CA 94303"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R. K.","family":"Alley","sequence":"additional","affiliation":[{"name":"Anacor Pharmaceuticals, Inc., Palo Alto, CA 94303"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Field","sequence":"additional","affiliation":[{"name":"The Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, DD1 5EH Dundee, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wyllie","sequence":"additional","affiliation":[{"name":"The Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, DD1 5EH Dundee, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5173-9284","authenticated-orcid":false,"given":"David","family":"Horn","sequence":"additional","affiliation":[{"name":"The Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, DD1 5EH Dundee, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","article-title":"Anti-trypanosomatid drug discovery: An ongoing challenge and a continuing need","volume":"15","author":"Field MC","year":"2017","unstructured":"MC Field, , Anti-trypanosomatid drug discovery: An ongoing challenge and a continuing need. Nat Rev Microbiol 15, 217\u2013231 (2017).","journal-title":"Nat Rev Microbiol"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1017\/S0031182016001268","article-title":"The animal trypanosomiases and their chemotherapy: A review","volume":"143","author":"Giordani F","year":"2016","unstructured":"F Giordani, LJ Morrison, TG Rowan, HP DE Koning, MP Barrett, The animal trypanosomiases and their chemotherapy: A review. Parasitology 143, 1862\u20131889 (2016).","journal-title":"Parasitology"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1586\/14787210.2014.959496","article-title":"Treatment options for second-stage gambiense human African trypanosomiasis","volume":"12","author":"Eperon G","year":"2014","unstructured":"G Eperon, , Treatment options for second-stage gambiense human African trypanosomiasis. Expert Rev Anti Infect Ther 12, 1407\u20131417 (2014).","journal-title":"Expert Rev Anti Infect Ther"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.pt.2018.04.002","article-title":"Melarsoprol resistance in African trypanosomiasis","volume":"34","author":"Fairlamb AH","year":"2018","unstructured":"AH Fairlamb, D Horn, Melarsoprol resistance in African trypanosomiasis. Trends Parasitol 34, 481\u2013492 (2018).","journal-title":"Trends Parasitol"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1017\/S0031182012000169","article-title":"Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis","volume":"139","author":"Simarro PP","year":"2012","unstructured":"PP Simarro, J Franco, A Diarra, JA Postigo, J Jannin, Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology 139, 842\u2013846 (2012).","journal-title":"Parasitology"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"e0003785","DOI":"10.1371\/journal.pntd.0003785","article-title":"Monitoring the progress towards the elimination of gambiense human African trypanosomiasis","volume":"9","author":"Simarro PP","year":"2015","unstructured":"PP Simarro, , Monitoring the progress towards the elimination of gambiense human African trypanosomiasis. PLoS Negl Trop Dis 9, e0003785 (2015).","journal-title":"PLoS Negl Trop Dis"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pt.2017.11.008","article-title":"Do cryptic reservoirs threaten gambiense-sleeping sickness elimination?","volume":"34","author":"B\u00fcscher P","year":"2018","unstructured":"P B\u00fcscher, , Do cryptic reservoirs threaten gambiense-sleeping sickness elimination? Trends Parasitol; Informal Expert Group on Gambiense HAT Reservoirs 34, 197\u2013207 (2018).","journal-title":"Trends Parasitol"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"e1151","DOI":"10.1371\/journal.pntd.0001151","article-title":"SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis","volume":"5","author":"Jacobs RT","year":"2011","unstructured":"RT Jacobs, , SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis 5, e1151 (2011).","journal-title":"PLoS Negl Trop Dis"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4155\/fmc.11.80","article-title":"Benzoxaboroles: A new class of potential drugs for human African trypanosomiasis","volume":"3","author":"Jacobs RT","year":"2011","unstructured":"RT Jacobs, , Benzoxaboroles: A new class of potential drugs for human African trypanosomiasis. Future Med Chem 3, 1259\u20131278 (2011).","journal-title":"Future Med Chem"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: A pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"Mesu VKBK","year":"2018","unstructured":"VKBK Mesu, , Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: A pivotal multicentre, randomised, non-inferiority trial. Lancet 391, 144\u2013154 (2018).","journal-title":"Lancet"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bmcl.2017.11.028","article-title":"Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of animal African trypanosomiasis (AAT)","volume":"28","author":"Akama T","year":"2018","unstructured":"T Akama, , Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of animal African trypanosomiasis (AAT). Bioorg Med Chem Lett 28, 6\u201310 (2018).","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1128\/AAC.00498-10","article-title":"Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system African trypanosomiasis","volume":"54","author":"Nare B","year":"2010","unstructured":"B Nare, , Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system African trypanosomiasis. Antimicrob Agents Chemother 54, 4379\u20134388 (2010).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/infdis\/jit420","article-title":"New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice","volume":"209","author":"Bustamante JM","year":"2014","unstructured":"JM Bustamante, JM Craft, BD Crowe, SA Ketchie, RL Tarleton, New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis 209, 150\u2013162 (2014).","journal-title":"J Infect Dis"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/srep04703","article-title":"Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: Implications for Chagas disease drug discovery and development","volume":"4","author":"Moraes CB","year":"2014","unstructured":"CB Moraes, , Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: Implications for Chagas disease drug discovery and development. Sci Rep 4, 4703 (2014).","journal-title":"Sci Rep"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.bmcl.2011.02.006","article-title":"Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties","volume":"21","author":"Li X","year":"2011","unstructured":"X Li, , Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties. Bioorg Med Chem Lett 21, 2048\u20132054 (2011).","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.bmcl.2011.02.024","article-title":"Synthesis and SAR of novel benzoxaboroles as a new class of \u03b2-lactamase inhibitors","volume":"21","author":"Xia Y","year":"2011","unstructured":"Y Xia, , Synthesis and SAR of novel benzoxaboroles as a new class of \u03b2-lactamase inhibitors. Bioorg Med Chem Lett 21, 2533\u20132536 (2011).","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1128\/AAC.02058-12","article-title":"Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria","volume":"57","author":"Hernandez V","year":"2013","unstructured":"V Hernandez, , Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria. Antimicrob Agents Chemother 57, 1394\u20131403 (2013).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.15252\/emmm.201607370","article-title":"Targeting Toxoplasma gondii CPSF3 as a new approach to control toxoplasmosis","volume":"9","author":"Palencia A","year":"2017","unstructured":"A Palencia, , Targeting Toxoplasma gondii CPSF3 as a new approach to control toxoplasmosis. EMBO Mol Med 9, 385\u2013394 (2017).","journal-title":"EMBO Mol Med"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"14574","DOI":"10.1038\/ncomms14574","article-title":"A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue","volume":"8","author":"Sonoiki E","year":"2017","unstructured":"E Sonoiki, , A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Nat Commun 8, 14574 (2017).","journal-title":"Nat Commun"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/17512433.2016.1206467","article-title":"Tavaborole: A treatment for onychomycosis of the toenails","volume":"9","author":"Gupta AK","year":"2016","unstructured":"AK Gupta, SG Versteeg, Tavaborole: A treatment for onychomycosis of the toenails. Expert Rev Clin Pharmacol 9, 1145\u20131152 (2016).","journal-title":"Expert Rev Clin Pharmacol"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","volume":"316","author":"Rock FL","year":"2007","unstructured":"FL Rock, , An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 316, 1759\u20131761 (2007).","journal-title":"Science"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/jpet.113.207662","article-title":"Linking phenotype to kinase: Identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors","volume":"347","author":"Akama T","year":"2013","unstructured":"T Akama, , Linking phenotype to kinase: Identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors. J Pharmacol Exp Ther 347, 615\u2013625 (2013).","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1016\/j.febslet.2012.07.058","article-title":"Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center","volume":"586","author":"Freund YR","year":"2012","unstructured":"YR Freund, , Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett 586, 3410\u20133414 (2012).","journal-title":"FEBS Lett"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"e0004299","DOI":"10.1371\/journal.pntd.0004299","article-title":"Genomic and proteomic studies on the mode of action of oxaboroles against the African trypanosome","volume":"9","author":"Jones DC","year":"2015","unstructured":"DC Jones, , Genomic and proteomic studies on the mode of action of oxaboroles against the African trypanosome. PLoS Negl Trop Dis 9, e0004299 (2015).","journal-title":"PLoS Negl Trop Dis"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"e0006450","DOI":"10.1371\/journal.pntd.0006450","article-title":"Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei","volume":"12","author":"Steketee PC","year":"2018","unstructured":"PC Steketee, , Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei. PLoS Negl Trop Dis 12, e0006450 (2018).","journal-title":"PLoS Negl Trop Dis"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature10771","article-title":"High-throughput decoding of antitrypanosomal drug efficacy and resistance","volume":"482","author":"Alsford S","year":"2012","unstructured":"S Alsford, , High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 482, 232\u2013236 (2012).","journal-title":"Nature"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"e1006850","DOI":"10.1371\/journal.ppat.1006850","article-title":"Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles","volume":"14","author":"Zhang N","year":"2018","unstructured":"N Zhang, , Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles. PLoS Pathog 14, e1006850 (2018).","journal-title":"PLoS Pathog"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1128\/AAC.03338-14","article-title":"Drug target identification using a trypanosome overexpression library","volume":"58","author":"Begolo D","year":"2014","unstructured":"D Begolo, E Erben, C Clayton, Drug target identification using a trypanosome overexpression library. Antimicrob Agents Chemother 58, 6260\u20136264 (2014).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"e1004178","DOI":"10.1371\/journal.ppat.1004178","article-title":"A genome-wide tethering screen reveals novel potential post-transcriptional regulators in Trypanosoma brucei","volume":"10","author":"Erben ED","year":"2014","unstructured":"ED Erben, A Fadda, S Lueong, JD Hoheisel, C Clayton, A genome-wide tethering screen reveals novel potential post-transcriptional regulators in Trypanosoma brucei. PLoS Pathog 10, e1004178 (2014).","journal-title":"PLoS Pathog"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"E3012","DOI":"10.1073\/pnas.1520693113","article-title":"Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite Leishmania","volume":"113","author":"Gazanion \u00c9","year":"2016","unstructured":"\u00c9 Gazanion, C Fern\u00e1ndez-Prada, B Papadopoulou, P Leprohon, M Ouellette, Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite Leishmania. Proc Natl Acad Sci USA 113, E3012\u2013E3021 (2016).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1126\/science.1112642","article-title":"The genome of the African trypanosome Trypanosoma brucei","volume":"309","author":"Berriman M","year":"2005","unstructured":"M Berriman, , The genome of the African trypanosome Trypanosoma brucei. Science 309, 416\u2013422 (2005).","journal-title":"Science"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S135583820099229X","article-title":"A new twist in trypanosome RNA metabolism: cis-splicing of pre-mRNA","volume":"6","author":"Mair G","year":"2000","unstructured":"G Mair, , A new twist in trypanosome RNA metabolism: cis-splicing of pre-mRNA. RNA 6, 163\u2013169 (2000).","journal-title":"RNA"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.molbiopara.2005.08.009","article-title":"Tagging a T. brucei RRNA locus improves stable transfection efficiency and circumvents inducible expression position effects","volume":"144","author":"Alsford S","year":"2005","unstructured":"S Alsford, T Kawahara, L Glover, D Horn, Tagging a T. brucei RRNA locus improves stable transfection efficiency and circumvents inducible expression position effects. Mol Biochem Parasitol 144, 142\u2013148 (2005).","journal-title":"Mol Biochem Parasitol"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1126\/science.7761835","article-title":"Inducible gene expression in trypanosomes mediated by a prokaryotic repressor","volume":"268","author":"Wirtz E","year":"1995","unstructured":"E Wirtz, C Clayton, Inducible gene expression in trypanosomes mediated by a prokaryotic repressor. Science 268, 1179\u20131183 (1995).","journal-title":"Science"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nprot.2015.005","article-title":"Genome-scale RNAi screens for high-throughput phenotyping in bloodstream-form African trypanosomes","volume":"10","author":"Glover L","year":"2015","unstructured":"L Glover, , Genome-scale RNAi screens for high-throughput phenotyping in bloodstream-form African trypanosomes. Nat Protoc 10, 106\u2013133 (2015).","journal-title":"Nat Protoc"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-pharmtox-011613-135915","article-title":"Antiparasitic chemotherapy: From genomes to mechanisms","volume":"54","author":"Horn D","year":"2014","unstructured":"D Horn, MT Duraisingh, Antiparasitic chemotherapy: From genomes to mechanisms. Annu Rev Pharmacol Toxicol 54, 71\u201394 (2014).","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nature08893","article-title":"N-myristoyltransferase inhibitors as new leads to treat sleeping sickness","volume":"464","author":"Frearson JA","year":"2010","unstructured":"JA Frearson, , N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 464, 728\u2013732 (2010).","journal-title":"Nature"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1021\/acsinfecdis.6b00034","article-title":"Global profiling and inhibition of protein lipidation in vector and host stages of the sleeping sickness parasite Trypanosoma brucei","volume":"2","author":"Wright MH","year":"2016","unstructured":"MH Wright, D Paape, HP Price, DF Smith, EW Tate, Global profiling and inhibition of protein lipidation in vector and host stages of the sleeping sickness parasite Trypanosoma brucei. ACS Infect Dis 2, 427\u2013441 (2016).","journal-title":"ACS Infect Dis"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1091\/mbc.e06-08-0736","article-title":"Trypanosoma brucei ARF1 plays a central role in endocytosis and Golgi-lysosome trafficking","volume":"18","author":"Price HP","year":"2007","unstructured":"HP Price, M Stark, DF Smith, Trypanosoma brucei ARF1 plays a central role in endocytosis and Golgi-lysosome trafficking. Mol Biol Cell 18, 864\u2013873 (2007).","journal-title":"Mol Biol Cell"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/emboj\/cdg481","article-title":"Clathrin-mediated endocytosis is essential in Trypanosoma brucei","volume":"22","author":"Allen CL","year":"2003","unstructured":"CL Allen, D Goulding, MC Field, Clathrin-mediated endocytosis is essential in Trypanosoma brucei. EMBO J 22, 4991\u20135002 (2003).","journal-title":"EMBO J"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1101\/gr.115089.110","article-title":"High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome","volume":"21","author":"Alsford S","year":"2011","unstructured":"S Alsford, , High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome. Genome Res 21, 915\u2013924 (2011).","journal-title":"Genome Res"},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1101\/gad.8.4.491","article-title":"A common pyrimidine-rich motif governs trans-splicing and polyadenylation of tubulin polycistronic pre-mRNA in trypanosomes","volume":"8","author":"Matthews KR","year":"1994","unstructured":"KR Matthews, C Tschudi, E Ullu, A common pyrimidine-rich motif governs trans-splicing and polyadenylation of tubulin polycistronic pre-mRNA in trypanosomes. Genes Dev 8, 491\u2013501 (1994).","journal-title":"Genes Dev"},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jb\/mvj183","article-title":"Crystal structure of TTHA0252 from Thermus thermophilus HB8, a RNA degradation protein of the metallo-\u03b2-lactamase superfamily","volume":"140","author":"Ishikawa H","year":"2006","unstructured":"H Ishikawa, N Nakagawa, S Kuramitsu, R Masui, Crystal structure of TTHA0252 from Thermus thermophilus HB8, a RNA degradation protein of the metallo-\u03b2-lactamase superfamily. J Biochem 140, 535\u2013542 (2006).","journal-title":"J Biochem"},{"key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"12406","DOI":"10.1038\/ncomms12406","article-title":"Structural basis of metallo-\u03b2-lactamase, serine-\u03b2-lactamase and penicillin-binding protein inhibition by cyclic boronates","volume":"7","author":"Brem J","year":"2016","unstructured":"J Brem, , Structural basis of metallo-\u03b2-lactamase, serine-\u03b2-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat Commun 7, 12406 (2016).","journal-title":"Nat Commun"},{"key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.1038\/s41598-018-26303-w","article-title":"Inducible high-efficiency CRISPR-Cas9-targeted gene editing and precision base editing in African trypanosomes","volume":"8","author":"Rico E","year":"2018","unstructured":"E Rico, L Jeacock, J Kov\u00e1\u0159ov\u00e1, D Horn, Inducible high-efficiency CRISPR-Cas9-targeted gene editing and precision base editing in African trypanosomes. Sci Rep 8, 7960 (2018).","journal-title":"Sci Rep"},{"key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.aao6535","article-title":"Architecture of eukaryotic mRNA 3\u2032-end processing machinery","volume":"358","author":"Casa\u00f1al A","year":"2017","unstructured":"A Casa\u00f1al, , Architecture of eukaryotic mRNA 3\u2032-end processing machinery. Science 358, 1056\u20131059 (2017).","journal-title":"Science"},{"key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nature05363","article-title":"Polyadenylation factor CPSF-73 is the pre-mRNA 3\u2032-end-processing endonuclease","volume":"444","author":"Mandel CR","year":"2006","unstructured":"CR Mandel, , Polyadenylation factor CPSF-73 is the pre-mRNA 3\u2032-end-processing endonuclease. Nature 444, 953\u2013956 (2006).","journal-title":"Nature"},{"key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mib.2016.04.018","article-title":"Gene expression in kinetoplastids","volume":"32","author":"Clayton CE","year":"2016","unstructured":"CE Clayton, Gene expression in kinetoplastids. Curr Opin Microbiol 32, 46\u201351 (2016).","journal-title":"Curr Opin Microbiol"},{"key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/15476286.2015.1130208","article-title":"The polyadenylation complex of Trypanosoma brucei: Characterization of the functional poly(A) polymerase","volume":"13","author":"Koch H","year":"2016","unstructured":"H Koch, M Raabe, H Urlaub, A Bindereif, C Preu\u00dfer, The polyadenylation complex of Trypanosoma brucei: Characterization of the functional poly(A) polymerase. RNA Biol 13, 221\u2013231 (2016).","journal-title":"RNA Biol"},{"key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"27982","DOI":"10.1074\/jbc.M109.095349","article-title":"Analysis of spliceosomal proteins in trypanosomatids reveals novel functions in mRNA processing","volume":"285","author":"Tkacz ID","year":"2010","unstructured":"ID Tkacz, , Analysis of spliceosomal proteins in trypanosomatids reveals novel functions in mRNA processing. J Biol Chem 285, 27982\u201327999 (2010).","journal-title":"J Biol Chem"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1807915115","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1807915115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T14:39:56Z","timestamp":1654612796000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1807915115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":50,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2018,9,18]]}},"alternative-id":["10.1073\/pnas.1807915115"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1807915115","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,5]]},"assertion":[{"value":"2018-09-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}